---
title: "BKKT: Q2 2026 saw sharply lower revenue but positive net income from a $98.5M Transchem gain"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295450039.md"
description: "Revenue and trading volumes declined sharply year-over-year due to the loss of major clients and market contraction, but net income turned positive in Q2 2026 due to a large unrealized gain on Transchem Warrants. Strategic acquisitions and investments were completed, and liquidity is sufficient for at least 12 months.Original document: Bakkt, Inc. [BKKT] SEC 10-Q Quarterly Report — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-10T20:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295450039.md)
  - [en](https://longbridge.com/en/news/295450039.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295450039.md)
generator: "portal-rs"
---

# BKKT: Q2 2026 saw sharply lower revenue but positive net income from a $98.5M Transchem gain

Revenue and trading volumes declined sharply year-over-year due to the loss of major clients and market contraction, but net income turned positive in Q2 2026 due to a large unrealized gain on Transchem Warrants. Strategic acquisitions and investments were completed, and liquidity is sufficient for at least 12 months.

Original document: Bakkt, Inc. \[BKKT\] SEC 10-Q Quarterly Report — Aug. 10 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BKKT.US](https://longbridge.com/en/quote/BKKT.US.md)
- [BKKT+.US](https://longbridge.com/en/quote/BKKT+.US.md)

## Related News & Research

- [Bakkt director Michael Alfred reports $2.11 million Class A share purchase](https://longbridge.com/en/news/296388550.md)
- [Walmart store workers have a new responsibility: correcting AI errors](https://longbridge.com/en/news/296213777.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [ZAPLOX: Q2 2026 saw a return to profitability and strong cost control, setting the stage for future growth](https://longbridge.com/en/news/296186495.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**